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Abstract
Background: An increasing number of studies have shown that ERK and PI3-K/AKT signaling
pathways are involved in various human cancers including hepatocellular carcinoma and
cholangiocarcinoma. However, few studies have examined gallbladder cancer specimens, and little
is known about the clinical and pathological significance of ERK1/2 and PI3-K/AKT signaling changes
in gallbladder adenocarcinoma. In this study, we examined phospho-ERK1/2 (p-ERK1/2) and PI3K
expression and analyzed its clinicopathological impact in gallbladder adenocarcinoma.
Methods: Immunohistochemistry was used to detect and compare the frequency of p-ERK1/2 and
PI3-K expression in gallbladder adenocarcinoma, peri-tumor tissues, adenomatous polyps, and
chronic cholecystitis specimens.
Results: The positive staining for p-EKR1/2 and PI3-K were 63/108 (58.3%) and 55/108 (50.9%) in
gallbladder adenocarcinoma; 14/46 (30.4%) and 5/46 (10.1%) in peri-tumor tissues; 3/15 (20%) and
3/15 (20%) in adenomatous polyps; and 4/35 (11.4%) and 3/35 (8.6%) in chronic cholecystitis. The
positive rate of p-ERK1/2 or PI3-K in gallbladder adenocarcinoma was significantly higher than that
in peri-tumor tissue (both, P < 0.01), adenomatous polyps (p-ERK1/2, P < 0.01; PI3-K, P < 0.05),
and chronic cholecystitis (both, P  < 0.01). The positive staining for p-ERK1/2 or PI3-K was
significantly lower in well/highly-differentiated adenocancinomas with maximal diameter < 2.0 cm,
no metastasis to lymph node, and no infiltration of regional tissues or organs compared to poorly-
differentiated adenocarcinomas which are characterized by a maximal diameter ≥ 2.0 cm, with
metastasis to lymph node and infiltration of regional tissues or organs (P < 0.05 or P < 0.01).
Moreover, the frequency of p-ERK1/2 expression in gallbladder adenocarcinomas without gallstone
was significantly lower than those with gallstones. Increased expression of p-ERK1/2 (P < 0.05) and
PI3K (P = 0.062) was associated with decreased overall survival. Multivariate Cox regression
analysis showed that increased p-ERK1/2 expression was an independent prognostic predictor in
gallbladder carcinoma (P = 0.028).
Conclusion:  Increased expression of p-ERK1/2 and PI3K might contribute to gallbladder
carcinogenesis. p-ERK1/2 over-expression is correlated with decreased survival and therefore may
serve as an important biological marker in development of gallbladder adenocarcinoma.
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Background
Gallbladder cancer is a relatively rare but terminal malig-
nancy occurring predominantly in elderly women. It
accounts for nearly two-thirds of biliary tract cancers,
making it the most common primary biliary cancer and
the fifth most common cancer of the gastrointestinal tract
[1,2]. More than 85% of gallbladder cancers belong to
adenocarcinomas that are often well or moderately differ-
entiated, and the remaining 15% are squamous, adenosq-
uamous or undifferentiated carcinomas. Surgery is the
only recommended treatment currently available. How-
ever, more than 70% of cases are un-resectable due to
local invasion into critical structures or metastasis beyond
regional confines. A better understanding of pathological
molecular mechanisms of gallbladder carcinogenesis may
provide insights for developing novel targeted therapies
for this deadly disease.
The development of cancer in man involves multiple
genetic changes that often lead to dysfunction of certain
signaling pathways controlling cell fate, cell growth, and
cell survival or cell death. Activation of the extracellular
signal-regulated kinase (ERK) 1/2 and PI3-K signaling
pathways is believed to be involved in the pathological
processes of cancer development. Activation of the ERK1/
2 pathway results in cell proliferation [3,4] and leads to
malignant transformation both in vitro and in vivo [5,6],
and activation of the PI3-K/AKT signaling pathway inhib-
its apoptosis and promotes cell survival. An increasing
number of studies have shown that both ERK and PI3-K/
Expression of p-ERK1/2 and PI3-K (original magnification 200×) Figure 1
Expression of p-ERK1/2 and PI3-K (original magnification 200×). Expression of p-ERK1/2 in well-differentiated gall-
bladder adenocarcinoma (a), moderately-differentiated gallbladder adenocarcinoma (b), and poorly-differentiated gallbladder 
adenocarcinoma (c); PI3-K expression in well-differentiated (d), moderately-differentiated (e), and poorly-differentiated gall-
bladder adenocarcinoma (f).
de f
ab cJournal of Experimental & Clinical Cancer Research 2009, 28:65 http://www.jeccr.com/content/28/1/65
Page 3 of 8
(page number not for citation purposes)
AKT signaling pathways are over-activated in various
human cancers including breast cancer, lung cancer,
colorectal cancer, pancreatic cancer, malignant
melanoma, hepatocellular carcinoma, and cholangiocar-
cinoma [6-9]. In hepatocellular carcinoma, activation of
ERK1/2 indicates aggressive tumor behavior and consti-
tutes an independent prognostic factor. Increased p-
ERK1/2 and p-AKT levels correlate with decreased overall
survival [10]. Elevated p-ERK1/2 and p-AKT expressions
have also been found in cholangiocarcinoma [7]. Both
EKR1/2 and AKT can be activated by a number of factors
including EGFR, inflammation signals mediated by
cytokine receptors, mutation of oncogenes such as Ras
and Raf, and bile acids [8].
Since few studies have examined gallbladder cancer speci-
mens [11], little is known about the clinical or pathological
significance of ERK1/2 and PI3-K/AKT signaling changes in
gallbladder adenocarcinoma. In this study, we examined
the frequency of p-ERK1/2 and PI3K expression in gallblad-
der adenocarcinoma specimens by means of immunohis-
tochemistry and attempt to elucidate the clinical and
pathological significance of changes in the p-ERK1/2 and
PI3-K/AKT pathways in gallbladder adenocarcinoma.
Methods
Materials
108 gallbladder carcinoma specimens were collected from
the First and Second Xiangya hospitals affiliated to Cen-
Immunohistochemical staining of p-ERK1/2 and PI3-K (original magnification 200×) Figure 2
Immunohistochemical staining of p-ERK1/2 and PI3-K (original magnification 200×). p-ERK1/2 expression in peri-
tumor tissues with severe atypical proliferation of gallbladder adenocarcinoma (a), in gallbladder adenoma polyps with moder-
ate atypical proliferation (b), in chronic cholecystitis with moderate atypical proliferation (c). PI3-K staining in surrounding tis-
sues with severe atypical proliferation of gallbladder adenocarcinoma (d), in gallbladder adenoma polyps with severe atypical 
proliferation pericancerous tissues (e), and in chronic cholecystitis with mild (f).
def
ab cJournal of Experimental & Clinical Cancer Research 2009, 28:65 http://www.jeccr.com/content/28/1/65
Page 4 of 8
(page number not for citation purposes)
tral South University, and People's Hospital of Hunan
Province, Changsha, China. 77 (71.3%) specimens came
from female patients and 31 males (28.7%). All speci-
mens were diagnosed as adenocarcinomas, of which 9
had adenoma lesions, 29 were highly differentiated, 29
moderately differentiated, 30 poorly differentiated, and
the remaining 11 were mucous adenomas (10.2%). Dur-
ing surgery, 59 cases (54.6%) were found to have invasion
of peri-cholecystic tissues and organs, 59 cases (54.6%)
demonstrated local lymph node metastases; and 58 cases
(53.7%) had evidence of gallstones/cholelithiasis. The
applied surgical modalities include radical resection in 34
cases (31.5%), palliative resection/operation in 48 cases
(44.4%), and 26 cases (24.1%) unresectable due to local
invasion into critical structures or metastasis beyond
regional confines. From the above 108 gallbladder aden-
ocarcinoma samples, we obtained the peri-tumor tissues
from 46 case (distance to adenocarcinomas ≥3 mm), 10 of
which were normal by pathological analysis. Mild, mod-
erate or severe atypical proliferation was observed in 10,
12 and 14 cases, respectively. 15 specimens of gallbladder
adenoma polyps were obtained from the Second Affili-
ated Hospital of Central South University (including 10
female and 5 male, average age 52 years old, range 42 to
60 years). The polyploidy adenomas ranged from 0.08 –
15 mm in size, 5 out of the 15 had moderate to severe pro-
liferation. In addition, 35 chronic cholecystitis specimens
were obtained (15 with chronic cholecystitis alone, 20
with chronic cholecystitis and gallstones) as controls. His-
tologically, the 35 specimens included 11 with normal
gallbladder mucosa, 12 with mild atypical proliferation, 7
with moderate atypical proliferation, and 5 with severe
atypical proliferation. All the above samples were fixed in
4% formalin, and 4 micron sections were prepared for
immunohistochemistry studies.
Immunohistochemistry
For p-ERK1/2 and PI3-K detection, immunostaining was
carried out using EnVision™ (ChemMate™EnVison +/
HRP/DAB, Rabbit/Mouse Two Step Staining Method)
Table 2: Expression of p-ERK1/2 and PI3-K as determined by immunohistochemistry, and clinicopathological variables in 108 patients 
with gallbladder adenocarcinoma.
Group Total pERK1/2 + (%) P value PI3-K + (%) P value
Sex
Female 77 47 (61.0) >0.05 41(53.2) >0.05
Male 31 16(51.6) 14(45.2)
Age
≤45 24 12(50) >0.05 12(50) >0.05
>45 84 51(60.7) 43(51.2)
Tumor diameter
<2.0 cm 31 13(41.9) <0.05 11(35.5) <0.05
≥2.0 cm 77 50(64.9) 44(57.1)
Lympho node metastasis
No 49 20(40.8) <0.01 16(32.7) <0.01
Yes 59 43(72.9) 39(66.1)
Surrounding tissue invasion
No 49 21(42.9) <0.01 17(34.7) <0.01
Yes 59 42(71.2) 38(64.4)
Gallstones
No 50 24(48.0) <0.05 22(44) >0.05
Yes 58 36(67.2) 33(56.9)
Table 1: Expression of p-ERK1/2 and PI3-K in gallbladder adenocarcinoma, surrounding tissues, adenomatous polyps, and chronic 
cholecystitis as determined by immunohistochemistry.
Disease type Total pERK1/2 + (%) P value PI3-K + (%) P value
Gallbladder adenocarcinoa 108 65/108 (58.3%) <0.01 55/108 (50.9%) <0.01
Surrounding tissues 46 14/46 (30.4%) 5/46 (10.1%)
Adenomatous polyps 15 3/15 (20%) 3/15 (20%)
Chronic cholecystitis 35 4/35 (11.4%) 3/35 (8.6%)Journal of Experimental & Clinical Cancer Research 2009, 28:65 http://www.jeccr.com/content/28/1/65
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according to the manufacture's protocol (DAKO laborato-
ries Inc, California, USA). Briefly, paraffin-embedded gall-
bladder adenocarcinoma tissues were cut into 4 μm thick
sections. The sections were de-paraffinized and incubated
with 3% of H2O2 solution for 15 min, followed by EDTA-
trypsinase digestion (0.125%, pH 9.0) for 15 min, then
soaked with PBS (pH7.4) 3 times, each for 5 minutes. The
pre-treated sections were then incubated with rabbit anti-
human p-ERK1/2 or PI3-K (Bosite Inc, Wuhan, China) for
60 min at room temperature. Solution A (Chem-
Mate™EnVison +/HRP) was added and incubated for
another 30 min. Substrate DAB liquid was added and fol-
lowed by hematoxylin counter-staining. Slides were dehy-
drated with different concentrations of alcohol and
soaked in xylene for 5 minutes (3 times), and then
mounted permanently with neutral balsam. Slides were
examined independently by two pathologists. The results
of p-ERK1/2 or PI-3K immunostaining were considered to
be positive when more than 25% of the tumor cells were
stained. The positive controls were provided by Bosite Inc,
Wuhan.
Statistical analysis
The SPSS13.0 program was used for calculation of interre-
lationships between the analyzed p-ERK1/2 or PI3-K and
histological or clinical factors by χ2 independence test.
Fisher's exact probability test was also used for analyzing
statistical association between the two independent sam-
ple groups. The results were considered to be significant
when the P value were less than 0.05. Disease specific
overall survival analyses were determined and compared
using the Kaplan-Meier method and the log-rank test. For
multivariate analysis the Cox regression method was per-
formed. 95% confidence intervals were used overall.
Results
Expression of p-ERK1/2 and PI3-K in human gallbladder 
adenocarcinoma, peri-tumor tissues, adenomatous polyps, 
and chronic cholecystitis
Immunohistochemistry for p-ERK1/2 and PI3-K were
conducted with 108 gallbladder adenocarcinomas, 46
surrounding tissues of gallbladder adenocarcinoma, 15
adenoma polyps, and 35 chronic cholecystitis samples.
Positive staining for p-ERK1/2 was observed in the cyto-
plasm and/or nucleus (Figure 1 and 2a–c). PI3-K staining
was mostly seen in the cytoplasm as expected (Figure 1
and 2d–f). As shown in Table 1, of the 108 gallbladder
adenocarcinomas, expression of p-ERK1/2 and PI3-K was
detected in 63 (58.3%) and 55 cases (50.9%), respec-
tively. In the 46 surrounding tissues of gallbladder adeno-
carcinoma, p-ERK1/2 and PI3-K were positive in 14
(30.4%) and 5 (10.1%) cases, respectively. Moderate to
severe atypical hyperplasia were observed in all gallblad-
der mucous epithelium in p-ERK1/2 positive cases. In PI3-
K positive samples, however, gallbladder mucous epithe-
lium was normal in one case, mild atypical hyperplasia in
one case, while moderate and severe atypical hyperplasia
were seen in one and 2 cases, respectively. Positive stain-
ing for p-ERK1/2 and PI3-K was both observed in 3 out of
15 adenoma polyps which all showed moderate to severe
atypical hyperplasia. In the chronic cholecystitis group, p-
ERK1/2 and PI3-K staining was positive in 4 (11.4%) and
3 (8.6%) of the 35 cases, respectively. Gallbladder
mucous epithelium in positive specimens showed moder-
ate to severe atypical hyperplasia. Overall, the frequency
of samples positive for p-ERK1/2 and PI3-K in gallbladder
adenocarcinomas was significantly higher than that in
surrounding tissues (χ2
pERK = 10.04, P  < 0.01; χ2
PI3-K =
21.77, P < 0.01), in adenoma polyps (χ2
pERK = 7.78, P <
0.01; χ2
PI3-K = 5.06, P < 0.01), and in chronic cholecystitis
(χ2
pERK = 23.35, P < 0.01; χ2
PI3-K = 19.67, P < 0.01).
Correlation of p-ERK1/2 and PI3-K expression with clinical 
and pathological features of gallbladder adenocarcinoma
We further analyzed the correlation of p-ERK1/2 and PI3-
K expression with the clinical and pathological features of
gallbladder adenocarcinoma. As shown in Table 2, the fre-
quency of samples staining positive for p-ERK1/2 and PI3-
K in cases with small tumor size (<2 cm in diameter),
without lymph node metastasis, and no invasion of sur-
rounding tissues was significantly lower than in cases with
larger tumor size (>2 cm), lymph node metastasis, and
invasion in surrounding tissues (P < 0.05 or P < 0.01).
Interestingly, the positive staining for p-ERK1/2 in cases
concomitant with gallstones/cholelithiasis was signifi-
cantly higher than in cases without gallstones (P < 0.05).
Table 3: p-ERK1/2 and PI3-K expression in gallbladder adenocarcinoma as determined by immunohistochemistry.
Total pERK1/2 + (%) P value PI3-K + (%) P value
Pathology type*
Adenoma canceration 9 3(33.3) 2(22.2)
Well-differentiated 29 12(41.4) <0.01 10(34.5) <0.01
Moderately-differentiated 29 18(62.1) 16(55.2)
Poorly-differentiated 30 25(83.3) 23(76.7)
Mucous adenoma 11 5(45.5) 4(36.4)
*Comparison of adenoma lesions and poorly-differentiated adenocarcinomas, PpERK = 0.08, PPI3-K = 0.05, comparison of the well-differentiated and 
poorly-differentiated, χ2
pERK = 11.10, P < 0.01; χ2
PI3-K = 10.65, P < 0.01.Journal of Experimental & Clinical Cancer Research 2009, 28:65 http://www.jeccr.com/content/28/1/65
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Moreover, positive staining for p-ERK1/2 and PI3-K in
adenoma or well-differentiated adenocarcinomas was sig-
nificantly lower compared to poorly-differentiated adeno-
carcinomas as shown in Table 3 (both, P < 0.01).
Correlation of p-ERK1/2 and PI3K expression with disease 
specific overall survival
After surgical resection, only 67 out of 108 patients were
able to be followed up via phone or mail surveys. Of the
67 cases with follow-up, 20 cases had over one year sur-
vival, and 47 died within one year after surgery, with a
mean survival time of 9.6 ± 5.2 months. 37 of the 67
(55.2%) patients had positive immunohistochemical
staining of p-ERK1/2, and 35 (52.2%) had positive PI3K
staining. The relevance of positive p- ERK1/2 and PI3K
expression to patients survival was examined by univari-
ate Kaplan-Meier survival analysis. Overall survival was
inversely associated with positive or increased expression
of p-ERK1/2 (P = 0.045) (Figure 3a) and PI3K (P = 0.062)
(Figure 3b). The relevance of overall survival and other
clinical pathological characteristics were also assessed by
univariate analysis which showed that the overall survival
was associated with tumor pathological type (P = 0.031),
tumor diameter (P = 0.003), lymph node metastasis (P =
0.005) and surrounding tissue invasion (P = 0.002). All
factors that showed significant association in the univari-
ate Kaplan-Meier analysis were subsequently subject to
multivariate Cox regression survival analysis, which indi-
cated that lymph node metastasis and surrounding tissue
invasion were the most significant predictors of short
overall survival, followed by p-ERK1/2 over-expression
(Table 4).
Discussion
In the present study, we examined p-ERK1/2 and PI3-K
expression by immunohistochemistry in 108 human gall-
bladder adenocarcinoma samples from separate individu-
als. 58.3% and 50.9% of the specimens showed strong
positive staining for p-ERK1/2 and PI3-K, respectively,
indicating that both p-ERK1/2 and PI3-K/AKT might be
potential biomarkers of gallbladder cancer. Compared to
benign lesions and peri-tumor tissues, positive staining
for p-ERK1/2 and PI3-K in gallbladder adenocarcinoma
was significantly higher. Expression of p-ERK1/2 and PI3-
K was correlated with a low grade of differentiation in ade-
nocarcinoma (Table 1). Moreover, p-ERK1/2 and PI3-K
staining was more frequently detected in gallbladder ade-
nocarcinoma cases with larger tumor size, lymph node
metastasis, and surrounding tissue invasion compared to
cases with smaller tumor size, without metastasis or tissue
invasion (Table 2). These findings suggest that activation
of both the p-ERK1/2 and PI-3K/AKT signaling pathways
might be involved in malignant transformation and pro-
gression of gallbladder adenocarcinoma. On multivariate
analysis, there was a significant association between p-
ERK1/2 over-expression and reduced survival (Table 4).
To our knowledge, this is the first report showing a corre-
lation of p-EKR1/2 and PI3-K expression with clinical and
pathological features, including tumor size, lymph node
metastasis and surround tissue invasion. Hori et al [11]
demonstrated that 77% of extra-hepatic biliary tract can-
cer showed positive staining for p-MAPK and 47% for p-
AKT. However, those results showed no positive correla-
tion between p-MAPK/p-AKT expression and clinical and
pathological features, including tumor stage and pT cate-
Kaplan-Meier plots for overall survival in 67 patients with  gallbladder carcinoma surgery in relation to p-ERK1/2 and  PI3K expression Figure 3
Kaplan-Meier plots for overall survival in 67 patients 
with gallbladder carcinoma surgery in relation to p-
ERK1/2 and PI3K expression. (a) Positive or increased p-
ERK1/2 expression was associated with reduced over sur-
vival (P = 0.045, log rank test). (b) Increased PI3K expression 
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gory in extra-hepatic biliary tract cancer. The study per-
formed by Hori et al was based on a small cohort with 30
patients including 15 with gallbldadder cancer, 13 with
bile duct cancer and 2 with ampullary cancer. Another
study by Wu et al. also revealed elevated level of p-AKT in
74.1% (20 of 27) of human gallbladder cancer specimens
[12]. A number of other studies showed similar positive
rates of expression of p-MAPK/p-ERK1/2 or p-AKT in
cholangiocarcinoma [7], intra-hepatic cholangiocarci-
noma [8], and cholangiocarcinoma [13], but the associa-
tion with clinical and pathological features remain
inconclusive. Javle et al. demonstrated that expression of
p-AKT may be associated with improved survival [13].
However, in another study Schmitz et al. showed that nei-
ther p-ERK1/2 nor p-AKT expression had an impact on
patients survival in a larger and more homogenous cohort
of solely intra-hepatic cholangiocarcinoma [8].
ERK1/2 and PI3-K signaling pathways are associated with
cell proliferation, transformation and survival. The exact
molecular mechanism in which ERK1/2 and/or AKT
remains constitutively activated in a variety of human can-
cers is however not well understood. EGFR activation trig-
gers multiple signaling cascades which include MAPK/
ERK1/2 and PI3-K/AKT pathways, resulting in cell prolif-
eration, differentiation, angiognenesis, metastasis, and
inhibition of apoptosis [14,15]. Over-expression of EGFR
was found in patients with malignancies of gallbladder,
ampullary and common bile duct [16-19]. Somatic muta-
tions of EGFR in the tyrosine kinase domain have been
identified in a subgroup of patients with cholangiocarci-
noma or gallbladder carcinoma [15]. The mutations lead
to sustained activation of signaling and results in cell sur-
vival and proliferation. Mutations of oncogenes have also
been identified in cholangiocarcinoma. For example, K-
Ras and B-Raf mutations were found in 22% and 45% of
cholangiocarcinoma, respectively [20]. Chronic inflam-
matory condition caused by gallstone or cholecystitis has
also been linked to the development of gallbladder can-
cer[21,22]. How chronic inflammation contributes to
gallbladder cancer and how inflammatory factors affect
EKR1/2 and PI-3K/AKT pathways in gallbladder cells is yet
to be explored. Several reports show that cholangiocarci-
noma cells constitutively secrete IL-6 which may activate
ERK1/2 and AKT [23-25]. In our study, 58 of the 108
(54%) patients had gallstones. Interestingly, activated
EKR1/2 but not PI3-K is correlated with presence of chole-
lithiasis (Table 2). The underlying mechanism needs to be
further studied.
Cross-talk between the ERK1/2 and PI3-K signaling path-
ways has been implied at different stages of cholangiocar-
cinoma and extrahepatic biliary tract cancers [11]. Our
study also indicates that there is a positive correlation
between the frequency of p-ERK1/2 and PI3-K expression,
suggesting a possible cross-talk of the two pathways in
gallbladder adenocarcinoma. Further studies to address
the underlying mechanisms in which activation of the
ERK and AKT pathways contributes to increased tumor
aggressiveness and progression in gallbladder adenocarci-
noma might offer the possibility to utilize serine/threo-
nine kinase inhibitors as targeted therapeutics.
Conclusion
Our study revealed that the frequency of p-ERK1/2 and
PI3-K expression is increased in gallbladder adenocarci-
noma. Activation of ERK1/2 and PI3-K signaling pathways
is correlated with decreased patients' survival. ERK1/2 and
PI3-K pathways may serve as new targets for furture devel-
opment of novel treatments for gallbladder adenocarci-
noma.
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